BioNTech, InstaDeep form AI lab
BioNTech and InstaDeep will form a joint artificial intelligence (AI) lab as part of a multiyear strategic collaboration.
Celltrion enrolls COVID-19 patients in treatment trial
Celltrion has enrolled patients with mild-to-moderate symptoms of SARS-CoV-2 infection in a phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment.
EC secures 80M doses of Moderna COVID-19 vaccine
Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.
Altimmune submits IND for single dose intranasal COVID-19 vaccine
Altimmune has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to begin a phase I clinical trial of its single-dose intranasal COVID-19 vaccine, AdCOVID.
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity efforts, including COVID-19 vaccine infrastructure.
Covaxx to deliver over 140M vaccine doses to emerging countries
Covaxx, a subsidiary of United Biomedical, has received purchase commitments of more than 140 million doses of its UB-612 COVID-19 vaccine, totaling over $2.8 billion. The vaccine will be delivered to multiple countries including Brazil, Ecuador, and Peru.
ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2.
Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.
City of Hope initiates SARS-CoV-2 vaccine phase I trial
The City of Hope has begun a phase I clinical trial of COH04S1, which is its investigational SARS-CoV-2 vaccine, in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
Older adults likely to get COVID-19 vaccine, but some say they want to wait
A new poll of older adults indicates that that there is some hesitancy among the group when asked if they would get an effective COVID-19 vaccine.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter